title: A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations.
abstract: Fleas are a common ectoparasite of domestic cats and there is a need for novel treatments that improve feline flea control.
  
  
  
  This investigator-blinded, multi-center randomized, positive-controlled study evaluated the flea control in cats provided by a single owner-applied treatment with a fluralaner topical formulation compared with a positive control. Households with up to five healthy cats, all at least 12 weeks of age and weighing at least 1.2 kg (2.6 lb), were randomized in an approximate 3:1 ratio of fluralaner to positive control. All cats in households randomized to the positive control group were dispensed three treatments, at 4-week intervals, of a commercial formulation of fipronil/(S)-methoprene. All cats in households randomized to the fluralaner group were dispensed an initial treatment at enrollment and a second treatment at week 12 for an additional 3-week observation of treatment safety. One primary cat with at least five live fleas at enrollment was randomly selected within each household. Flea counts were performed on all primary cats at 4-week intervals through week 12. Efficacy measurement was based on reduction in flea counts from baseline. Treatment was considered effective at weeks 4, 8 and 12 if mean live flea count reductions were 90% or greater and statistically significantly different (P ≤ 0.05) from counts at enrollment.
  
  
  
  In 18 investigational veterinary clinics across 11 USA states, 116 households (224 cats) were randomized to receive topical fluralaner and 45 households (87 cats) were randomized to the fipronil-methoprene combination. Fluralaner was demonstrated to be effective at 4 weeks (99.1% flea count reduction), 8 weeks (99.5%), and 12 weeks (99.0%), and all reductions were significantly different from the enrollment count (all P < 0.0001). The fipronil-methoprene combination was < 90% effective at each post-treatment assessment, with peak efficacy of 75.4% at 12 weeks (all P < 0.0001). No treatment-related serious adverse events were reported in either group.
  
  
  
  Owner-applied fluralaner topical treatment was safe in cats and was highly effective in killing fleas over the subsequent 12 weeks.
authors.affiliation: Merck Animal Health, Madison, NJ, USA. cheyney.meadows@merck.com.
authors.forename: Cheyney
authors.initials: C
authors.lastname: Meadows
authors.affiliation: Merck Animal Health, Madison, NJ, USA.
authors.forename: Frank
authors.initials: F
authors.lastname: Guerino
authors.affiliation: Merck Animal Health, Madison, NJ, USA.
authors.forename: Fangshi
authors.initials: F
authors.lastname: Sun
mesh_terms: D000287:Administration, Topical; D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy* / Q000517:prevention & control*; D002415:Cats; D058267:Flea Infestations / Q000188:drug therapy / Q000517:prevention & control / Q000662:veterinary*; D007306:Insecticides / Q000008:administration & dosage* / Q000009:adverse effects; D007555:Isoxazoles / Q000008:administration & dosage* / Q000009:adverse effects; D059208:Parasite Load; D016037:Single-Blind Method; D012996:Solutions / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014481:United States
chemical_list: C000591860:A1443 compound; D007306:Insecticides; D007555:Isoxazoles; D012996:Solutions
keywords: Bravecto; Cats; Fipronil-methoprene; Fleas; Fluralaner